Absorption, Distribution and Excretion of [14C] Zamicastat after Single Oral and Intravenous Administration in Rats and Dogs

Abstract

BackgroundZamicastat is a dopamine‐β‐hydroxylase inhibitor (1), previously showed to increase the survival rate in the monocrotaline rat model of pulmonary arterial hypertension.ObjectivesThe purpose of this study was to characterize the absorption, distribution and elimination of 14C‐zamicastat in rat and dog, after single oral (p.o.) or intravenous (i.v.) administration.MethodsWistar rats and Beagle dogs were administered with 14C‐zamicastat at 30 mg/kg orally or intravenously with 2.5 mg/kg (rat) and 0.1 mg/kg (dog). Plasma, urine and faeces samples were collected at different time‐points to measure the plasma exposure and the recovery of total radioactivity up to 168 h post‐dose. Whole body phosphor imaging (WBPI) was evaluated in rat after p.o. administration of 30 mg/kg of 14C‐zamicastat. The extent of plasma protein binding was determined by equilibrium dialysis and blood cell binding was determined, using centrifugation, on pooled male samples from each species.ResultsAfter single oral dosing of 14C‐zamicastat, more than 95% of total radioactivity was recovered at five and seven days from rats and dogs, respectively. The radioactivity peaked in plasma between 6 to 8 h and 2 to 4 h post‐dosing in rats and dogs, respectively, followed by a slow elimination over time. Zamicastat related radioactivity was mainly recovered in faeces with very low levels (less than 20% of total radioactivity) excreted in urine in both species. Following i.v. administration more than 80% of radioactivity was recovered in both species mainly via feaces excretion. The WBPI study indicates that radioactivity was distributed throughout the body with the majority of tissues achieving a tissue:blood ratio greater than 2. Elimination of radioactivity progressed over time with most tissues reaching the low limit of quantification at 168h. The highest tissue:blood ratios were noted in thyroid gland, lung and harderian gland at, respectively, 168h, 8h and 8h post‐dosing. Protein binding data indicates that zamicastat is preferentially bound to plasma proteins in a concentration independent manner, with 98% and 96% bound to rat and dog plasma proteins, respectively.ConclusionZamicastat is a highly plasma protein bound compound after oral administration and it is extensively distributed to tissues. After oral administration to rats and dogs, radioactivity was almost completely recovered with most of zamicastat‐related radioactivity excreted through faeces.